All Episodes

Pier Luigi Zinzani, MD, PhD - Recognising and Responding to a Rare Disease: A Case-Based Exploration of the Ideal iMCD Patient Journey

Matthew J. Koster, MD - VEXAS Syndrome Asked and Answered: Everything You Want To Know And More

Francesco Passamonti, MD - Myelofibrosis Under the Microscope: Exploring p53 Dysregulation as a Potential Therapeutic Target

Steven Horwitz, MD - Relapsed/Refractory Peripheral T-Cell Lymphoma: Reviewing Available and Anticipated Strategies in This Rare Malignancy

Sanjay Popat, FRCP, PhD - Don’t Forget About HER2: Clinical Insights and Novel Therapies for HER2-Mutant NSCLC From ESMO 2025

Nadia Harbeck, MD, PhD - Antibody-Drug Conjugates in Breast Cancer: Keeping Abreast of the Latest Data As They Emerge From ESMO

Fred Saad, MD, FRCS - From Platform to Practice: Insights From ESMO 2025 on the Latest Data Guiding Contemporary Care in mHSPC and nmCRPC

Naveen Pemmaraju, MD - How I Treat BPDCN: A Case-Based Exploration of Best Practices in Selecting and Providing Therapeutic Strategies

Alicia K. Morgans, MD, MPH - Clinical Conversations in Castration-Resistant Prostate Cancer: Best Practices in Discussing Testing and Treatment With Patients

Alison Birtle, FRCP, FRCR, MD - Case Study Challenge in Advanced Bladder Cancer: Tailoring Treatment to Individual Patients

Robert J. Motzer, MD - Advanced Renal Cell Carcinoma: Clinical Advances in Approaches to Combination Therapy

Diana N. Ionescu, MD - To Target We Need to Test: Why and How to Identify Folate Receptor Alpha-Positive Ovarian Cancer

Alessandro M. Vannucchi, MD, PhD - Not All JAKis Are Equal: What Can Trials and Real-World Evidence Tell Us About Optimal Treatment Approaches in Myelofibrosis?

Amrita Krishnan, MD - The Specifics of Bispecific Antibodies for Multiple Myeloma

Claire Harrison, DM, FRCP, FRCPath - Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations on Treatment Goals and Decisions

Michael K. Wong, MD, PhD, FRCPC - When Anti-PD1 Therapy Fails: Could Oncolytic Immunotherapy Impact Outcomes in Advanced Melanoma?

John Mascarenhas, MD - Working With Our Patients as Partners in Care: Addressing Disease- and Treatment-Related Burdens Associated With Cytopenic Myelofibrosis

Richard Kim, MD - The Modern Art of Sequencing Later Lines of Treatment for Advanced Colorectal Cancer: Exploring Case Scenarios With the Experts

Peter Schmid, FRCP, MD, PhD - Staying at the Forefront of HER2 and TROP2-Directed Antibody-Drug Conjugate Advances in Breast Cancer

Diana N. Ionescu, MD - Pathological Assessment of HER2 Status in Gastric and Gastroesophageal Cancers: Important Steps That Can Impact Outcomes

Andrea Necchi, MD - Practical Considerations for ADC-ICI Combinations in Advanced Urothelial Carcinoma: Identifying and Managing Adverse Events

Simron Singh, MD, MPH - Addressing the Challenges of Treating Highly Proliferative Neuroendocrine Tumours: Review of the Latest Evidence

Elizabeth Smyth, MD, FRCP - When They Need More Than Trastuzumab: Deciding on What’s Next for Patients With HER2+ Gastric Cancer

Richard Kim, MD - From Trial Protocol to Routine Practice: Evaluating Real-World Evidence for Later-Line Treatments in Advanced Colorectal Cancer

Brandon Blue, MD - Challenging Racial Disparities in Multiple Myeloma Treatment and Outcomes: Local Solutions to Address an Endemic Problem

María-Victoria Mateos, MD, PhD - Updates in Multiple Myeloma From Madrid: Data Surrounding BCMA-Directed Agents and Their Clinical Relevance

Shaji Kumar, MD - Age Is More Than Just a Number: Tailoring Treatment Across the Multiple Myeloma Journey for Our Older and/or Unfit Patients

Andrea Necchi, MD - Familiar Tools, New Uses? Assessing Novel Combination Approaches in the First-Line Management of Advanced Urothelial Carcinoma

Jeffrey Szer, MBBS, FRACP - The Quest for Optimal Haemolytic Control of Paroxysmal Nocturnal Haemoglobinuria

Dirk Arnold, MD - Navigating Decisions With Limited Tools: A Review of Best Practices in Managing Metastatic Colorectal Cancer

Amy E. DeZern, MD, MHS - Small Words Make Large Differences: Best Practices in Supporting MDS Patients Across All Stages of Their Journey

Elena Castro, MD, PhD - Radioligand Therapy and Therapeutic Sequencing in mCRPC

Karim Fizazi, MD, PhD - Radioligand Therapy for Prostate Cancer: Predicting Who May Benefit and Who May Not

Ken Herrmann, MD, MBA - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses

Aditya Bardia, MD, MPH - When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates for Hormone Receptor-Positive and Triple-Negative Breast Cancers

Karim Fizazi, MD, PhD - The Science and the Art of Modern Prostate Cancer Care: Improving Patient Outcomes Through Intensification and Individualisation of Treatment

Gilles Salles, MD, PhD - Differentiating Decisions in Transplant-Ineligible Relapsed/Refractory DLBCL: What Are Our Options, and How Do We Choose Between Them?

Amit Singal, MD, MS - Recognising the Rationale and Understanding the Outcomes for CTLA-4 Targeted Therapies in Advanced HCC

Johnny Mahlangu, MBBCH, MMed, FCPath - Redefining Balance in Hemophilia: Can We Restore Hemostasis by Inhibiting Anticoagulation?

Kevin Harrington, PhD, FRCR, FRCP - After More Than a Decade: Can We Now Enhance Treatment of Patients With LA SCCHN?

Sara A. Hurvitz, MD, FACP - Clinical Case Challenge: Implementing ADCs Into Routine mTNBC Treatment Plans

Aditya Bardia, MD, MPH - Keeping to Target in mTNBC: Optimising Outcomes With Antibody-Drug Conjugates in Practice

Emmanuella Guenova, MD, PhD - ‘T’ing Up Management of Mycosis Fungoides and Sézary Syndrome: Evaluating Blood Involvement and Its Impact on Patient Care

Jun-ichi Nishimura, MD, PhD / Austin Kulasekararaj, MD, FRCPath / Jeffrey Szer, MBBS, FRACP - Haemolysis in Paroxysmal Nocturnal Haemoglobinuria: Applying Assessment and Mitigation Strategies for Patients Receiving Complement Inhibitors

Alicia K. Morgans, MD, MPH - What Would You Do Next? Exploring Expert Perspectives on Clinical Cases and Compelling Questions in mHSPC and nmCRPC

Mary Frances McMullin, MD, FRCP, FRCPath - Managing Myelofibrosis: Can We Do More to Address Cytopenias, Reduce Transfusion Burden, and Improve Quality of Life?

Silke Gillessen, MD - Optimal Treatment of mCRPC: What Is the Place of Radioligand Therapy?

Isabelle Ray-Coquard, MD, PhD - Turning Advanced Ovarian Cancer Into a Chronic Disease One Step at a Time

Mohamad Mohty, MD, PhD - Veno-Occlusive Disease: Who to Treat, How to Treat, When to Treat

Rana R. McKay, MD - Practice Series on Translating Data Into Practice in mCRPC: The Evolving Role of Radiopharmaceuticals

Contemporary Management of Prostate Cancer: Updated Approaches for Improved Outcomes in nmCRPC and mHSPC

IAP Antagonists in Oncology: What Do We Know?

Personalising Management of Advanced RCC: How I Treat

Immunotherapeutic Approaches in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Insights From the Real World

The Place of Radiopharmaceuticals in an Evolving Treatment Landscape: Addressing Perceptions With Clinical Evidence to Optimise Outcomes in Men With Metastatic Prostate Cancer